Oncolytics Biotech Inc (ONC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Oncolytics Biotech Inc (Oncolytics) is a development stage biopharmaceutical company which focuses on the discovery and development of oncolytic viruses for use as cancer therapeutics. The Company’s lead product, Reolysin, a formulation of the human reovirus, is at Phase II clinical trials for the treatment of lung, ovarian, colorectal, pancreatic, prostate, breast, head and neck cancers. Reolysin is also undergoing various other clinical trials to determine its use in other types of cancer, such as for squamous cell carcinoma, metastatic colorectal cancer, metastatic melanoma trial, and non-small cell lung cancer. The company and its partners are conducting clinical trials in several countries across the world, including Canada, the US and the UK. Oncolytics is headquartered in Calgary, Alberta, Canada.
Oncolytics Biotech Inc Key Recent Developments
Jan 19, 2017: Oncolytics Biotech Appoints Dr. Matt Coffey to the Role of President and CEO
Dec 06, 2016: Oncolytics Biotech announces resignation of board member
Nov 10, 2016: Oncolytics Biotech Announces Appointment of New Chief Medical Officer
Nov 03, 2016: Oncolytics Biotech Announces 2016 Third Quarter Results
Nov 02, 2016: Oncolytics Biotech Announces Management Team Changes
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Section 1 - About the Company 6
Oncolytics Biotech Inc - Key Facts 6
Oncolytics Biotech Inc - Key Employees 7
Oncolytics Biotech Inc - Key Employee Biographies 8
Oncolytics Biotech Inc - Major Products and Services 9
Oncolytics Biotech Inc - Pharmaceutical Pipeline Products Data 10
Oncolytics Biotech Inc, Pipeline Products by Therapy Area 10
Oncolytics Biotech Inc, Pipeline Products by Development Phase 11
Oncolytics Biotech Inc - History 12
Oncolytics Biotech Inc - Company Statement 15
Oncolytics Biotech Inc - Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Section 2 – Company Analysis 18
Oncolytics Biotech Inc - Business Description 18
Oncolytics Biotech Inc - Corporate Strategy 19
Oncolytics Biotech Inc - SWOT Analysis 20
SWOT Analysis - Overview 20
Oncolytics Biotech Inc - Strengths 20
Oncolytics Biotech Inc - Weaknesses 21
Oncolytics Biotech Inc - Opportunities 22
Oncolytics Biotech Inc - Threats 23
Oncolytics Biotech Inc - Key Competitors 24
Section 3 – Company Financial Ratios 25
Financial Ratios - Capital Market Ratios 25
Financial Ratios - Annual Ratios 26
Performance Chart 27
Financial Performance 27
Financial Ratios - Interim Ratios 28
Financial Ratios - Ratio Charts 29
Section 4 – Company’s Lifesciences Financial Deals and Alliances 30
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 30
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 31
Oncolytics Biotech Inc, Recent Deals Summary 32
Section 5 – Company’s Recent Developments 33
Jan 19, 2017: Oncolytics Biotech Appoints Dr. Matt Coffey to the Role of President and CEO 33
Dec 06, 2016: Oncolytics Biotech announces resignation of board member 34
Nov 10, 2016: Oncolytics Biotech Announces Appointment of New Chief Medical Officer 35
Nov 03, 2016: Oncolytics Biotech Announces 2016 Third Quarter Results 36
Nov 02, 2016: Oncolytics Biotech Announces Management Team Changes 37
Aug 04, 2016: Oncolytics Biotech Announces 2016 Second Quarter Results 38
May 06, 2016: Oncolytics Biotech Announces 2016 First Quarter Results 39
Mar 24, 2016: Oncolytics Biotech Announces Filing of Management Information Circular and Details of 2016 Annual General Meeting 40
Mar 11, 2016: Oncolytics Biotech Announces 2015 Year End Results 41
Section 6 – Appendix 43
Methodology 43
Ratio Definitions 43
About GlobalData 47
Contact Us 47
Disclaimer 47
List of Tables
Oncolytics Biotech Inc, Key Facts 6
Oncolytics Biotech Inc, Key Employees 7
Oncolytics Biotech Inc, Key Employee Biographies 8
Oncolytics Biotech Inc, Major Products and Services 9
Oncolytics Biotech Inc, Number of Pipeline Products by Therapy Area 10
Oncolytics Biotech Inc, Number of Pipeline Products by Development Stage 11
Oncolytics Biotech Inc, History 12
Oncolytics Biotech Inc, Subsidiaries 17
Oncolytics Biotech Inc, Key Competitors 24
Oncolytics Biotech Inc, Ratios based on current share price 25
Oncolytics Biotech Inc, Annual Ratios 26
Oncolytics Biotech Inc, Interim Ratios 28
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 30
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 31
Oncolytics Biotech Inc, Recent Deals Summary 32
Currency Codes 43
Capital Market Ratios 43
Equity Ratios 44
Profitability Ratios 44
Cost Ratios 45
Liquidity Ratios 45
Leverage Ratios 45
Efficiency Ratios 46
List of Figures
Oncolytics Biotech Inc, Pipeline Products by Therapy Area 10
Oncolytics Biotech Inc, Pipeline Products by Development Phase 11
Oncolytics Biotech Inc, Performance Chart (2011 - 2015) 27
Oncolytics Biotech Inc, Ratio Charts 29
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 30
Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 31